The business concept is centered on developing a science-backed Ayurvedic pharmaceutical solution specifically for dengue treatment, addressing a critical gap where current allopathic options largely focus only on symptom management rather than curing the disease. The company combines traditional Ayurvedic knowledge with modern scientific research and validation to create an effective, root-cause-based treatment for dengue. At the core of the business is its flagship product, Pyrexium DS, an innovative formulation designed with antiviral and immunomodulatory properties to help combat the dengue virus, improve platelet count, and reduce recovery time. Unlike existing treatments, the product focuses on treating the disease itself rather than just managing symptoms, making it a differentiated and impactful solution in the dengue treatment space. Importantly, the company has already achieved strong scientific progress, having conducted pre-clinical studies (both in-vitro and in-vivo) that establish the safety and efficacy of the product against dengue. These studies have shown significant antiviral activity and positive impact on key health parameters. Additionally, the company is working in collaboration with leading scientists and reputed research institutions, further strengthening the credibility and scientific backing of the product. The business follows a B2B2C model, targeting doctors (both Ayurvedic and allopathic), pharmacies, and end consumers, ensuring wide adoption and accessibility. With a focus on cost-effectiveness, minimal side effects, and compatibility with modern medicine, the company aims to make dengue treatment more effective and accessible at scale. Overall, the concept is to build a new category of evidence-based Ayurvedic medicines, starting with dengue, and expand into broader disease areas, positioning the company at the intersection of Ayurveda, biotechnology, and modern healthcare innovation.
Show MoreYear of Establishment2023